Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell non-Hodgkin?s lymphoma (NHL) affecting patients of all
ages with a wide range of clinical presentations. Even though DLBCL is curable in advanced stages, up to one-third of
patients will not achieve cure with initial therapy. In the modern era of rituximab-containing therapy given as initial treatment,
the prognosis for patients who require salvage therapy is poor and most of them will eventually succumb to their disease.
Insight into the complex molecular circuitry of DLBCL reveals a diverse range of somatic mutations and aberrant intracellular
signaling pathways that characterize distinct molecular subsets. The next major breakthrough in DLBCL therapy during this
?molecular era? of disease definition will be identification of combinations of novel agents that target the oncogenic drivers of
these DLBCL subsets. Results from recent landmark clinical trials with translational molecular investigations will be presented
in the context of advancement towards precision medicine. Additional data regarding molecular monitoring of DLBCL after
therapy will also be presented.
Mark Roschewski received his BA from the University of Notre Dame in 1997 and MD from the University of Nebraska Medical Center in 2001. He completed his
Hematology-Oncology Fellowship in 2009 at Walter Reed Army Medical Center (WRAMC) in Washington DC, where he served as the Director of Hematologic
Diseases at WRAMC for 3 years. He joined the Center for Cancer Research at the NCI in 2013 where his current role is as an Associate Clinical Investigator in the
Lymphoid Malignancies Branch with research focused on aggressive lymphomas and multiple myeloma.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals